Abstract Details

Title UCSF ICH Grading System Is a Better Prognostic Tool for Spontaneous Intracerebral Hemorrhage When Assessed at 24 Hours after the Event

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) S32 - (-)

Poster/Presentation
Number 005

Objective

Background Spontaneous intracranial hemorrhage (ICH) comprises approximately a fifth of all strokes. The University of California, San Francisco (UCSF) proposed a grading scale for prognostication of ICH patients consisting of five components: GCS, age, infra-tentorial involvement, presence of intraventricular hemorrhage (IVH) at admission, and ICH volume. The relationship between ICH score on admission and outcomes has been shown in our previous studies.

Design/Methods We conducted a retrospective analysis of patients who suffered a spontaneous ICH between July 2009 and June 2012 at a community teaching hospital. All variables of ICH score at admission,24 hours, and mRS at discharge were measured. Using the outlining method to measure hematoma, total volume of ICH was calculated by taking the sum of the hematoma area on individual slices multiplied by the thickness of each slice. We excluded those who did not have a CT scan within the 24 hour window or the necessary variables for correlation. The data was analyzed for strength of associations in respect to initial ICH score and 24 hour ICH score using SPSS software version 20.

Results Out of 265 patients, 116 were included (mean age was 68.90 +/- 14.70 69% male). Patients had a significantly higher mean ICH score at 24 hours than at admission, p < 0.05. Please refer to the table for association values.

Conclusions Our data suggests that there is a significant correlation of both initial and 24-hours ICH score with mRS. However, there is a stronger correlation in using 24 hour ICH score in predicting both mortality and degree of disability or dependence in patients with ICH. Therefore, ICH score at 24 hours can be taken into consideration when predicting patient's prognosis.

Authors/Disclosures
Mohammad Moussavi, MD PRESENTER	Dr. Moussavi has nothing to disclose.
Siddhart K. Mehta, MD	Dr. Mehta has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Jawad F. Kirmani, MD	Dr. Kirmani has nothing to disclose.
Brian Hunter, PhD (Novartis Pharma AG)	Brian Hunter has received personal compensation for serving as an employee of Novartis. Brian Hunter has received stock or an ownership interest from Novartis.

��ɫ��

��ɫ��